Rexulti - Otsuka Pharmaceutical Co., Ltd.
Por um escritor misterioso
Descrição
Rexulti - Otsuka Pharmaceutical Co., Ltd.
FDA approves treatment for agitation associated with dementia created by Princeton-based Otsuka
REXULTI Drug Insight and Market Forecast - 2032
Otsuka America Pharmaceutical 59148003813 - McKesson Medical-Surgical
Otsuka Contract Pharma
Pharmaceutical Business Products
New patent for Otsuka drug REXULTI – DrugPatentWatch - Make Better Decisions
FDA Approves Rexulti for Agitation Associated With Dementia Due to Alzheimer's Disease
Otsuka Pharmaceutical and Lundbeck present positive results showing reduced agitation in patients with Alzheimer's dementia treated with brexpiprazole at the 2022 Alzheimer's Association International Conference
Otsuka Pharmaceutical Co., Ltd. - BIO International Convention
11.22.23 Otsuka in FDA doghouse over Rexulti marketing claims; Madrigal nabs Dupixent launch lead as new CCO - Questex
Home Otsuka US
de
por adulto (o preço varia de acordo com o tamanho do grupo)
